Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation

Current Medical Research and Opinion

Volumn 21, Issue 4, 2005, Pages 483-487

  Hing, Jeremy P ^a   Piotrovsky, Vladimir ^b   Kimko, Hui ^a   Brashear, H Robert ^a   Zhao, Qinying ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; Extended release; Galantamine; Modeling and simulation; Pharmacokinetics

Indexed keywords

GALANTAMINE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; EXTENDED DRUG RELEASE; HUMAN; IMMEDIATE DRUG RELEASE; PARAMETER; POPULATION MODEL; PREDICTION; SIMULATION; STEADY STATE; TABLET FORMULATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADSORPTION; ALZHEIMER DISEASE; BIOLOGICAL AVAILABILITY; CAPSULES; CHOLINESTERASE INHIBITORS; DELAYED-ACTION PREPARATIONS; GALANTAMINE; HUMANS; MODELS, THEORETICAL; TABLETS;

EID: 18744410425     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X38213     Document Type: Article

References (12)

1. Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8
2. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D, on behalf of the Galantamine International-2 Study Group. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95
3. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C, and the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76
4. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321:1445-9
5. Yamada H, Sugiyama T, Ashida T, Ohwaki H, Fujii J. Medication management skill and regimen compliance are deteriorated in the elderly even without obvious dementia. Yakugaku Zasshi 2001;121:187-90
6. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
8. Brodaty H, Yan B, Damaraju CV, Gold M. Safety and tolerability of once-daily galantamine prolonged-release capsule in patients with mild to moderate Alzheimer's disease. Poster presented at: 8th European Federation of Neurological Societies; September 4-7, 2004; Paris, France
9. Piotrovsky V, Van Peer A, Van Osselaer N, Armstrong M, Aerssens J. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol 2003;43:514-23
10. Kewitz H. Pharmacokinetics and metabolism of galanthamine. Drugs Today 1997;33:265-72
11. Mihailova D, Yamboliev I, Zhivkova Z, Tencheva J, Jovovich V. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989;39:50-8
12. REMINYL [package insert]. Titusville, NJ. Janssen Pharmaceutica Products, LP; 2003